Sandoz Sets Out Expectations For US Humira Competition

Dedicated Q&A With Company Covers US Launch Of Hyrimoz Adalimumab Biosimilar

 
• By Dave Wallace

Acknowledging an “unprecedented” competitive landscape for adalimumab biosimilars in the US, Sandoz has spoken to Generics Bulletin about its expectations for its Hyrimoz rival to Humira.

Company sign reading Sandoz A Novartis Division
Sandoz discusses its recent US adalimumab biosimilar launch • Source: Shutterstock

More from Biosimilars

More from Products